A Systematic Review of the Risk of Non-alcoholic Fatty Liver Disease in Women With Polycystic Ovary Syndrome.

Autor:	Shahbaz M; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Almatooq H; Dermatology, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Foucambert P; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Esbrand FD; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Zafar S; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Panthangi V; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Cyril Kurupp AR; Pediatrics, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Raju A; Pediatrics, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Luthra G; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Khan S; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2022 Oct 04; Vol. 14 (10), pp. e29928. Date of Electronic Publication: 2022 Oct 04 (Print Publication: 2022).
DOI:	10.7759/cureus.29928
Abstrakt:	Polycystic ovary syndrome (PCOS) is a complex hormonal disorder associated with complications throughout various body organs. Previous studies have shown evidence of liver disease in some women with PCOS. In this study, we attempted to explore the risk of non-alcoholic fatty liver disease (NAFLD) in PCOS women and the specific factors involved in its development. We searched PubMed, PubMed Central, Medline, and ScienceDirect for articles related to the topic, screened those articles according to our inclusion/exclusion criteria, and conducted a thorough quality check using various quality appraisal tools to select articles relevant to our research. The process was conducted according to Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) Checklist 2020. We selected 11 high-quality observational studies for our review. Studies from various countries were included, and all studies demonstrated an increased prevalence of NAFLD in PCOS patients compared to healthy controls. Although insulin resistance, obesity, and increased androgens contribute to the increase in the risk of NAFLD in these patients, hyperandrogenism was the most influential risk factor in four of these studies. Two studies explored the degree of NAFLD in these patients using transient elastography (TE). They concluded that PCOS was significantly associated with hepatic steatosis (HS) rather than hepatic fibrosis in most patients. PCOS patients have an increased risk of developing NAFLD, particularly HS, and hyperandrogenism seems to be the main determinant. Therefore, effort should be put into screening and monitoring these patients to manage the disease. TE may be a useful method for monitoring the natural history of NAFLD in these patients, which requires further exploration. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2022, Shahbaz et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu